ArriVent BioPharma, Inc. AVBP Business Segments
| FY'25 | FY'24 | ||
|---|---|---|---|
| Research And Development Expense Product With Specified Ingredient by Product | |||
| Drug Firmonertinib Favour | $397K+46.0% | $272K-80.5% | |
| Drug Firmonertinib Further | $9.84M-19.8% | $12.27M-35.0% | |
| Drug Firmonertinib Furvent | $48.74M+42.8% | $34.14M+31.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does ArriVent BioPharma, Inc. break its business down?
- ArriVent BioPharma, Inc. (AVBP) reports research and development expense product with specified ingredient by product across 3 parts — Drug Firmonertinib Favour, Drug Firmonertinib Further and Drug Firmonertinib Furvent. Each is extracted from the segment footnotes and tracked over time.
- Where does ArriVent BioPharma, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in ArriVent BioPharma, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.